Primary Central Nervous System Lymphoma

Primary Central Nervous System Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

145 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 55
Recruiting: 38
Ph III recruiting: 5
Growth YoY: —
Industry share: 15%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (10)

clinicaltrialsPublishedShowing 1–49 of 49 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04688151	Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.	completed	Phase 1	22	National Health Research Institutes, TaiwanOTHER	1	Sep 17, 2026	clinicaltrials
NCT04462328	Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma	active not recruiting	Phase 1	25	Washington University School of MedicineOTHER	1	Sep 16, 2026	clinicaltrials